{
    "root": "d328a518-17cf-49d2-af3c-bbe4b5057613",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Enalapril Maleate",
    "value": "20250507",
    "ingredients": [
        {
            "name": "ENALAPRIL MALEATE",
            "code": "9O25354EPJ"
        },
        {
            "name": "Lactose Monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "Sodium Bicarbonate",
            "code": "8MDF5V39QO"
        },
        {
            "name": "CI 77491",
            "code": "1K09F3G675"
        }
    ],
    "indications": null,
    "contraindications": null,
    "warningsAndPrecautions": "Product:    50090-3275\n                  NDC:    50090-3275-0   30 TABLET in a BOTTLE\n                  NDC:    50090-3275-1   100 TABLET in a BOTTLE, PLASTIC \n                  NDC:    50090-3275-4   90 TABLET in a BOTTLE, PLASTIC",
    "adverseReactions": "Enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.\n                  Do not coadminister aliskiren with enalapril maleate in patients with diabetes (see \n                        PRECAUTIONS, Drug Interactions\n                     ).\n                  Enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see \n                        WARNINGS, Head and Neck Angioedema\n                     )."
}